In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

High Yield Municipal Fund A Shares (without sales charge*) posted a return of 0.77% in Q3 2025. It underperformed the S&P ...

Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...

Katapult Holdings, Inc. (NASDAQ: KPLT) Q3 2025 Earnings Call Transcript November 12, 2025 Katapult Holdings, Inc. beats ...

Coronal mass ejections, or CMEs, are large clouds of ionized gas called plasma and magnetic fields that erupt from the sun’s outer atmosphere. When these outbursts are directed at Earth, they can ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Good morning, and thank you for joining us today to discuss our fiscal 2026 first quarter results. On the call with me today ...

Diamond drilling at Majorodam, Suriname confirms the presence of a mineralized zone at least 800 m long at Heuvel Main in ...

GIB (NYSE) cgi.com/newsroom Fourth quarter revenue up 9.7% year-over-year Announces 13% increase to its dividend Q4-F2025 performance highlights F2025 ...

Tariff cost outlook -- Cost of sales in fiscal Q2 2026 is expected to see a 1%-3% tariff impact, returning to 1% for the remainder of fiscal 2026. Capital expenditure focus -- John H. Batten said ...

Infrastructure adjusted EBITDA in the third quarter of 2025 -- $23.5 million, up $2.6 million from the prior year period, ...

Robust balance sheet with access to over A$86.3M in funding comprising of, A$17.5M in cash, US$43.4M (A$65.5M) 24 month award from the U.S. Department of War to support antimony production in Alaska ...